ARTICLE | Clinical News
Tasigna nilotinib regulatory update
August 30, 2010 7:00 AM UTC
Swissmedic approved Tasigna nilotinib from Novartis for first-line treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase. The BCR-ABL tyrosine kinase i...